Cinven is reviewing strategic options for laboratory-services company Synlab International GmbH including a potential sale, people with knowledge of the matter said.
The private equity firm has been speaking with potential advisers and could start a sale process early next year, the people said, asking not to be identified because the information is private. Cinven plans to seek a valuation of about 5.5 billion euros ($6 billion) including debt for Augsburg, Germany-based Synlab, one of the people said.
A sale of Synlab would likely attract other private equity firms, the people said. No final decision has been made, and Cinven could elect to keep the business, the people said. A spokeswoman for Cinven declined to comment, while Synlab didn’t answer phone calls seeking comment.
Cinven first invested in Synlab in June 2015, buying a majority stake from fellow private equity firm BC Partners for about 1.7 billion euros, Bloomberg News reported at the time. It combined the business with Labco SA, which it agreed to buy earlier that year for 1.2 billion euros.
Synlab, led by Chief Executive Officer Mathieu Floreani, also counts Novo A/S and Ontario Teachers’ Pension Plan as minority investors, according to its website. It operates across more than 40 countries, handling more than 500 million clinical tests annually, according to Synlab’s website.
Cinven also owns stakes in retailer Kurt Geiger and German drugmaker Stada Arzneimittel AG, according to its website.
The sale plan comes at a time when Cinven’s rival Apax Partners is also weighing a sale of diagnostic services business Unilabs. The buyout firm is working with advisers at Rothschild & Co. to look at options for the business, people familiar with the matter said last week.
Source: Bloomberg
Can’t stop reading? Read more
Goldman Sachs launches Capital Solutions Group to boost private equity financing
Goldman Sachs unveiled its Capital Solutions Group, a new division aimed at strengthening its focus on financing solutions for private equity sponsors. The group combines the firm’s corporate finance, leveraged finance, and equity capital markets teams into one unit....
Private equity-backed Shein, Monzo & BrewDog to potentially IPO in London this year
London IPO market looks to bounce back with prominent listings in 2025. The London Stock Exchange will potentially rebound in 2025 following a difficult 2024, where IPO activity hit its lowest levels since the financial crisis. A range of high-profile companies from...
Hildred Capital closes $800m healthcare private equity fund
Hildred Capital Management closed its third fund, Hildred Equity Partners III, raising over $800m. The fund, which surpassed its $600m target and reached its hard cap in seven months, is more than double the size of its predecessor, which closed in 2021 with $363m....